Synthetic Biologics, Inc. announced that it has entered into a securities purchase agreement for the private placement of 275,000 Series C convertible preferred shares and 100,000 Series D convertible preferred shares at a price of $8 per share for gross proceeds of approximately $3 million with returning investor MSD Credit Opportunity Master Fund, L.P., a fund managed by MSD Partners, L.P. on July 28, 2022. The Series C convertible preferred shares and Series D convertible preferred shares have a conversion price of $1.22. The securities are subject to transfer restrictions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.364 USD | -9.90% | -9.68% | -15.37% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.37% | 6.24M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Theriva Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.